Search / Trial NCT06232447

Menthol, Inflammation, and Nicotine Transition Study

Launched by ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE · Jan 22, 2024

Trial Information

Current as of October 04, 2024

Recruiting

Keywords

Description

The goal of this study is to examine how switching from menthol (MC) to non-menthol (NMC) cigarette smoking may impact biomarkers of systemic inflammation, smoking behavior, and subjective responses related to smoking. MC smokers (N=68) will be recruited for a five-week study, with one-week of baseline of MC smoking (Phase 1), followed by four weeks of switching to study-provided, brand-matched NMCs (Phase 2). Biomarkers of systemic inflammation and tobacco exposure will be analyzed from blood samples before, during, and after switching for four weeks (baseline, week 1, week 3, and week 5)....

Gender

ALL

Eligibility criteria

  • Inclusion criteria
  • * Men and women between 21-85 years old
  • * Currently uses menthol cigarettes
  • * Daily smoking rate of ≥5 cigarettes/day for ≥1 year
  • * Currently own and regularly use an iOS/Android smartphone device able to download the LifeData application
  • * Able to read and communicate fluently in English
  • Exclusion criteria
  • * Currently pregnant or breastfeeding
  • * Actively trying to quit smoking
  • * Current heavy alcohol use
  • * Frequent use of non-menthol cigarettes, other smoking products, marijuana, or illicit substances
  • * History of severe medical/psychiatric condition or treatment

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

North Chicago, Illinois, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0